The medicines watchdog has slapped safety warnings on all oral anticoagulants following post-marketing reports of anticoagulant-related nephropathy presenting as acute kidney injury.

On Thursday, the TGA urged doctors to be aware of the “rare but serious” adverse event that resulted from profuse glomerular bleeding with the potential to cause irreversible kidney damage and death.

The product information for all oral anticoagulants marketed in Australia — apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban (Xarelto) and warfarin (Coumadin, Marevan) — now carries a warning on the risk of anticoagulant-related nephropathy (ARN).

“Early detection and intervention of ARN is critical to minimising its associated morbidity and mortality … Awareness of this adverse event among health professionals is important,” the TGA said.